ToledoHomo sapiens (Human)Cancer cell line

Also known as: TOLEDO

🤖 AI SummaryBased on 13 publications

Quick Overview

Human B-cell lymphoma cell line with known mutations and drug sensitivity profiles.

Detailed Summary

The Toledo cell line is a human B-cell lymphoma cell line derived from a patient with diffuse large B-cell lymphoma (DLBCL). It is characterized by specific genetic mutations and has been used in studies related to drug resistance and therapeutic targeting. The cell line exhibits high BCL-2 expression, making it sensitive to BCL-2 inhibitors like venetoclax. Research has shown that Toledo cells are part of the DLBCL subtype and have been utilized in investigations of molecular mechanisms underlying lymphoma progression and treatment responses. Additionally, the cell line has been involved in studies examining the role of somatic mutations in lymphomagenesis and the development of targeted therapies.

Research Applications

Drug resistance studiesTherapeutic targeting of BCL-2Molecular mechanisms of lymphoma progressionSomatic mutation analysis

Key Characteristics

High BCL-2 expressionSensitivity to BCL-2 inhibitorsUsed in DLBCL research
Generated on 6/20/2025

Basic Information

Database IDCVCL_3611
SpeciesHomo sapiens (Human)
Tissue SourcePeripheral blood[UBERON:UBERON_0000178]

Donor Information

Age CategoryAdult
SexFemale
Racecaucasian

Disease Information

DiseaseDiffuse large B-cell lymphoma
LineageLymphoid
SubtypeDiffuse Large B-Cell Lymphoma, NOS
OncoTree CodeDLBCLNOS

DepMap Information

Source TypeATCC
Source IDACH-000285_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTP53p.Glu198fs (c.592_596del5)Unspecified-Unknown
MutationSimpleKRASp.Gly13Asp (c.38G>A)HeterozygousSomaticfrom parent cell line MDA-MB-231

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
12
D13S317
11
D16S539
9
D18S51
12
D19S433
15,15.2
D21S11
28,32.2
D2S1338
19,23
D3S1358
16,18
D5S818
10,12
D7S820
9,10
D8S1179
13
FGA
19,22
Penta D
11,13
Penta E
10,12
TH01
8,9.3
TPOX
8,11
vWA
16,17
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.

Yang H.H., Koeffler H.P.

BMC Cancer 18:940.1-940.13(2018).

Smoothened stabilizes and protects TRAF6 from degradation: a novel non-canonical role of smoothened with implications in lymphoma biology.

Lossos I.S., Landgraf R., Vega-Vazquez F.

Cancer Lett. 436:149-158(2018).

Strategic therapeutic targeting to overcome venetoclax resistance in aggressive B-cell lymphomas.

Medeiros L.J., Ford R.J. Jr., Nomie K., Zhang L., Wang M.

Clin. Cancer Res. 24:3967-3980(2018).

Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma.

Pham L.V.

Oncotarget 9:346-360(2018).

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

High-throughput RNA sequencing-based virome analysis of 50 lymphoma cell lines from the Cancer Cell Line Encyclopedia project.

O'Grady T., Baddoo M., Fewell C., Renne R., Flemington E.K.

J. Virol. 89:713-729(2015).

Genetic heterogeneity of diffuse large B-cell lymphoma.";

Dunson D.B., Dave S.S.

Proc. Natl. Acad. Sci. U.S.A. 110:1398-1403(2013).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

Kutok J.L., Shipp M.A.

Blood 116:3268-3277(2010).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Expression of the ULBP ligands for NKG2D by B-NHL cells plays an important role in determining their susceptibility to rituximab-induced ADCC.

Mori F., Ding J.-M., Komatsu H., Iida S., Ueda R.

Int. J. Cancer 125:212-221(2009).

Copy number abnormalities, MYC activity, and the genetic fingerprint of normal B cells mechanistically define the microRNA profile of diffuse large B-cell lymphoma.

Robetorye R.S., Aguiar R.C.T.

Blood 113:6681-6690(2009).

Somatic mutations and intraclonal variations in the rearranged Vkappa genes of B-non-Hodgkin's lymphoma cell lines.

Gabay C., Ben-Bassat H., Schlesinger M., Laskov R.

Eur. J. Haematol. 63:180-191(1999).

Web Resources